Skip to main content
. 2024 Oct 31;17(11):1459. doi: 10.3390/ph17111459

Figure 1.

Figure 1

Rates of events in the INVICTUS trial in the Rivaroxaban and VKA arms. [VKA—Vitamin K antagonist].